Inventor · disambiguated record
Artem Shvartsbart
Also filed as: Shvartsbart Artem
20 granted patents·8 pending applications·74 citations·filing 2016–2025
93Inventor score
Top patents by PatentIndex Score
28 records- 0197US10065963B2Heterocyclic compounds as PI3K-γ inhibitorsINCYTE CORP·Filed 2016·Granted Sep 4, 2018·16 cites·14 claims
- 0296US10472368B2Heterocyclic compounds as PI3K-γ inhibitorsINCYTE CORP·Filed 2018·Granted Nov 12, 2019·12 cites·28 claims
- 0395US11225486B2Tertiary alcohols as PI3K-γ inhibitorsINCYTE CORP·Filed 2020·Granted Jan 18, 2022·4 cites·51 claims
- 0493US11926630B2Tertiary alcohols as PI3K-γ inhibitorsINCYTE CORP·Filed 2021·Granted Mar 12, 2024·2 cites·2 claims
- 0593US10975088B2Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitorsINCYTE CORP·Filed 2019·Granted Apr 13, 2021·6 cites·13 claims
- 0693US10479795B2Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitorsINCYTE CORP·Filed 2018·Granted Nov 19, 2019·13 cites·45 claims
- 0790US11046658B2Aminopyrazine derivatives as PI3K-γ inhibitorsINCYTE CORP·Filed 2019·Granted Jun 29, 2021·4 cites·23 claims
- 0888US10738057B2Tertiary alcohols as PI3K-γ inhibitorsINCYTE CORP·Filed 2018·Granted Aug 11, 2020·5 cites·38 claims
- 0987US12012409B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2021·Granted Jun 18, 2024·2 cites·48 claims
- 1087US11161838B2Heterocyclic derivatives as PI3K inhibitorsINCYTE CORP·Filed 2019·Granted Nov 2, 2021·4 cites·39 claims
- 1186US11091491B2Heterocyclic compounds as PI3K-y inhibitorsINCYTE CORP·Filed 2019·Granted Aug 17, 2021·4 cites·37 claims
- 1283US11078204B2Heterocyclic derivatives as PI3K inhibitorsINCYTE CORP·Filed 2019·Granted Aug 3, 2021·2 cites·46 claims
- 1382US2025388553A1AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORSINCYTE CORP·Filed 2025·Application pending·0 cites
- 1480US11939328B2Quinoline compounds as inhibitors of KRASINCYTE CORP·Filed 2022·Granted Mar 26, 2024·0 cites·35 claims
- 1579US12378243B2Quinoline compounds as inhibitors of KRASINCYTE CORP·Filed 2024·Granted Aug 5, 2025·0 cites·34 claims
- 1675US12030885B2Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitorsINCYTE CORP·Filed 2021·Granted Jul 9, 2024·0 cites·20 claims
- 1775US11773102B2Heterocyclic compounds as PI3K-γ inhibitorsINCYTE CORP·Filed 2021·Granted Oct 3, 2023·0 cites·27 claims
- 1874US2025368641A1Quinoline compounds as inhibitors of krasINCYTE CORP·Filed 2025·Application pending·0 cites
- 1970US12421197B2Aminopyrazine derivatives as PI3K-γ inhibitorsINCYTE CORP·Filed 2021·Granted Sep 23, 2025·0 cites·28 claims
- 2067US2025074916A1Brm targeting compounds and associated methods of usePRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2164US12006320B2Heterocyclic derivatives as PI3K inhibitorsINCYTE CORP·Filed 2021·Granted Jun 11, 2024·0 cites·33 claims
- 2259US2024165244A1BRM Targeting Compounds And Associated Methods Of UsePRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2359US2024190886A1BRM Targeting Compounds and Associated Methods of UsePRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2457US2023365576A1BRM Targeting Compounds And Associated Methods Of UsePRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2557US2023226040A1Combination therapy comprising an fgfr inhibitor and a kras inhibitorINCYTE CORP·Filed 2022·Application pending·0 cites
- 2653US2021355121A1Fused tricyclic kras inhibitorsINCYTE CORP·Filed 2021·Application pending·0 cites
- 2749US11566028B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2020·Granted Jan 31, 2023·0 cites·69 claims
- 2844US11306079B23-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitorsINCYTE CORP·Filed 2018·Granted Apr 19, 2022·0 cites·58 claims
Join the waitlist — get patent alerts
Get an alert when Artem Shvartsbart files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →